Back to Search
Start Over
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
- Source :
-
European Journal of Medicinal Chemistry . Jan2019, Vol. 162, p612-630. 19p. - Publication Year :
- 2019
-
Abstract
- Abstract We report structure-activity relationships of 1-arylsulfonyl indoline based benzamides. The benzamide (9) exhibits striking tubulin inhibition with an IC 50 value of 1.1 μM, better than that of combretastain A-4 (3), and substantial antiproliferative activity against a variety of cancer cells, including MDR-positive cell lines with an IC 50 value of 49 nM (KB), 79 nM (A549), 63 nM (MKN45), 64 nM (KB-VIN10), 43 nM (KB-S15), and 46 nM (KB-7D). Dual inhibitory potential of compound 9 was found as it demonstrated significant inhibitory potential against HDAC1, 2 and 6 in comparison to MS-275 (6). Some key interactions of 9 with the amino acid residues of the active site of tubulin and with amino acid residues of HDAC 1 isoform have been figured out by molecular modeling. Compound 9 also demonstrated significant in vivo efficacy in the human non-small cell lung cancer A549 xenograft model as well as B-cell lymphoma BJAB xenograft tumor model. Graphical abstract Image 1 Highlights • A series of 1-Arylsulfonyl Indoline-Benzamides has been synthesized. • Compound 9 remarkably suppressed the growth of cancer cell lines. • The benzamide 9 displayed striking tubulin inhibition. • Compound 9 exhibited significant inhibitory potential against HDAC 1, 2 and 6. • Compound 9 also demonstrated significant in vivo efficacy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 02235234
- Volume :
- 162
- Database :
- Academic Search Index
- Journal :
- European Journal of Medicinal Chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 133720744
- Full Text :
- https://doi.org/10.1016/j.ejmech.2018.10.066